Investor Relations

Explore information about IDEAYA's business, strategy, pipeline, and financial performance, as well as the latest updates for the investment community.

Download IDEAYA Highlights

Stock Info
NASDAQIDYA

View all stock information

Recent News
Jun 3, 2026
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1...

Jun 1, 2026
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO

Darovasertib combination resulted in a statistically significant and clinically meaningful improvement in median PFS vs. investigator's choice of therapy (ICT) – 6.9 months vs. 3.1 months, HR:...

May 29, 2026
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on May 28, 2026, the...

All Releases

Events
AI Panel at the 2026 Jefferies Global Healthcare Conference
Thursday, June 4, 2026
8:45am EDT

Panel discussion featuring Yujiro S. Hata, President and Chief Executive Officer, moderated by Akash Tewari, Global Head of Biopharmaceutical Research

2026 Jefferies Global Healthcare Conference
Wednesday, June 3, 2026
7:35am EDT

Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, Biotechnology

All Events